Ferrara Mariantonia, Loda Alessandra, Coco Giulia, Grassi Piergiacomo, Cestaro Silvia, Rezzola Sara, Romano Vito, Semeraro Francesco
Manchester Royal Eye Hospital, Oxford Road, Manchester M13 9WL, UK.
Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123 Brescia, Italy.
J Clin Med. 2023 Jan 24;12(3):912. doi: 10.3390/jcm12030912.
Diabetic retinopathy (DR), the most common microvascular complication of diabetes mellitus, represents the leading cause of acquired blindness in the working-age population. Due to the potential absence of symptoms in the early stages of the disease, the identification of clinical biomarkers can have a crucial role in the early diagnosis of DR as well as for the detection of prognostic factors. In particular, imaging techniques are fundamental tools for screening, diagnosis, classification, monitoring, treatment planning and prognostic assessment in DR. In this context, the identification of ocular and systemic biomarkers is crucial to facilitate the risk stratification of diabetic patients; moreover, reliable biomarkers could provide prognostic information on disease progression as well as assist in predicting a patient's response to therapy. In this context, this review aimed to provide an updated and comprehensive overview of the soluble and anatomical biomarkers associated with DR.
糖尿病视网膜病变(DR)是糖尿病最常见的微血管并发症,是劳动年龄人群后天性失明的主要原因。由于该病早期可能没有症状,临床生物标志物的识别在DR的早期诊断以及预后因素检测中起着关键作用。特别是,成像技术是DR筛查、诊断、分类、监测、治疗规划和预后评估的基本工具。在这种情况下,眼部和全身生物标志物的识别对于促进糖尿病患者的风险分层至关重要;此外,可靠的生物标志物可以提供疾病进展的预后信息,并有助于预测患者对治疗的反应。在此背景下,本综述旨在提供与DR相关的可溶性和解剖学标志物的最新全面概述。